A Phase 2 interventional study of Pegcetacoplan in C3G, IC-MPGN and Renal Transplant, sponsored by Apellis Pharmaceuticals, Inc.. Completed at 25 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Glomerulonephritis, Membranoproliferative with a site in United States — 1 open to participants now, 2 under way, 2 of them phase 3. Glomerulonephritis, Membranoproliferative · United States.
Among the 15 studies in Glomerulonephritis, Membranoproliferative with a site in United States, this one is the 8th largest by enrollment, is one of 2 that started in 2021, is one of 7 in phase 2, and was the 13th registered.
33 studies on the registry are indexed under Glomerulonephritis, Membranoproliferative; 10 are open to participants now.
Browse Glomerulonephritis, Membranoproliferative studies →1 of the 15 studies in Glomerulonephritis, Membranoproliferative with a site in United States is open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Brazil and 14 more countries
Ages 12–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Glomerulonephritis, Membranoproliferative studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 22 across 26 interventional studies indexed under Glomerulonephritis, Membranoproliferative.
Median enrollment 13 across the 15 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Apellis Pharmaceuticals, Inc., one of the names counted as Biogen. Under that name alone:
Apellis Pharmaceuticals, Inc. is the lead sponsor of 28 studies on the registry; 3 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Biogen has 5 studies filed under Glomerulonephritis, Membranoproliferative — fewer than ten, so there is no comparison to draw.
1 of the studies in Glomerulonephritis, Membranoproliferative with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05809531Phase 3Apellis Pharmaceuticals, Inc.An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Glomerulonephritis, Membranoproliferative with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients who have post-transplant recurrence of C3G or IC-MPGN.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pegcetacoplan treatment of 1080 mg (sub-cutaneous infusion) twice weekly will be given throughout the entire study.
Drug: Pegcetacoplan
No intervention given during the randomized controlled portion of the study (through week 12). After week 12, subjects will receive pegcetacoplan treatment.
Drug: Pegcetacoplan
Complement (C3) Inhibitor
Percentage of Subjects With Reduction in C3c Staining on Renal Biopsy at Week 12
C3c staining intensity is semi quantitatively graded on a scale of 0 to 3, in which negative, 1+, 2+ and 3+ staining corresponds to scores of 0 to 3, with 0 being absent and 3 being the highest intensity seen on immunofluorescence. Higher scores indicate worse outcome. Reduction in C3c staining was defined as decrease of at least 2 orders of magnitude of intensity from baseline. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.
Time frame: Baseline (Day 1) and Week 12
Percentage of Subjects With Reduction in C3c Staining on Renal Biopsy at Week 52
C3c staining intensity is semi quantitatively graded on a scale of 0 to 3, in which negative, 1+, 2+ and 3+ staining corresponds to scores of 0 to 3, with 0 being absent and 3 being the highest intensity seen on immunofluorescence. Higher scores indicate worse outcome. Reduction in C3c staining was defined as decrease of at least 2 orders of magnitude of intensity from baseline. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.
Time frame: Baseline (Day 1) and Week 52
Number of Subjects With Shift of C3c Staining From Baseline to Weeks 12 and 52
C3c staining intensity is semi quantitatively graded on a scale of 0 to 3, in which negative, 1+, 2+ and 3+ staining corresponds to scores of 0 to 3, with 0 being absent and 3 being the highest intensity seen on immunofluorescence. Higher scores indicate worse outcome. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects. Number of subjects who demonstrated a shift of C3c staining from baseline to Week 12 and baseline to Week 52 are presented.
Time frame: Baseline (Day 1), Week 12 and Week 52
Percentage of Subjects With Stabilization or Improvement in Estimated Glomerular Filtration Rate (eGFR) at Week 52
eGFR was calculated by using Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) creatinine equation. Stabilization or improvement in eGFR was defined as no more than a 25% decrease relative to baseline. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.
Time frame: Baseline (Day 1) and Week 52
Percentage of Subjects With Stabilization or Improvement of Serum Creatinine Concentration at Week 52
Stabilization or improvement in serum creatinine was defined as no increase or an increase of no more than 25% from baseline. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.
Time frame: Baseline (Day 1) and Week 52
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52
Blood samples were collected at specified timepoints for analysis of eGFR which was calculated by using CKD-EPI creatinine equation. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.
Time frame: Baseline (Day 1) and Week 52
Percentage Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52
Blood samples were collected at specified timepoints for analysis of eGFR which was calculated by using CKD-EPI creatinine equation. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.
Time frame: Baseline (Day 1) and Week 52
Change From Baseline in Serum Creatinine Concentration at Week 52
Blood samples were collected at specified timepoints for analysis of serum creatinine concentration. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.
Time frame: Baseline (Day 1) and Week 52
Percentage Change From Baseline in Serum Creatinine Concentration at Week 52
Blood samples were collected at specified timepoints for analysis of serum creatinine concentration. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.
Time frame: Baseline (Day 1) and Week 52
This phase 2, open-label study was conducted in subjects with post-transplant recurrence of complement 3 glomerulopathy (C3G) or immune complex membranoproliferative glomerulonephritis (IC-MPGN) at 23 sites across 11 countries. First subject was recruited on 07 September 2021 and data cut-off (DCO) date was 19 January 2024.
| Milestone | Part A: Controlled Portion: Group 1 | Part A: Controlled Portion: Group 2 | Part A: Non-controlled Portion: Group 1 | Part A: Non-controlled Portion: Group 2 |
|---|---|---|---|---|
| Started | 10 | 3 | 0 | 0 |
| Completed | 10 | 3 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Part A: Controlled Portion: Group 1 | Part A: Controlled Portion: Group 2 | Part A: Non-controlled Portion: Group 1 | Part A: Non-controlled Portion: Group 2 |
|---|---|---|---|---|
| Started | 0 | 0 | 10 | 3 |
| Completed | 0 | 0 | 8 | 2 |
| Not completed | 0 | 0 | 2 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
C3c staining intensity is semi quantitatively graded on a scale of 0 to 3, in which negative, 1+, 2+ and 3+ staining corresponds to scores of 0 to 3, with 0 being absent and 3 being the highest intensity seen on immunofluorescence. Higher scores indicate worse outcome. Reduction in C3c staining was defined as decrease of at least 2 orders of magnitude of intensity from baseline. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.
| Percentage of participants | Part A: Controlled Portion: Group 1 | Part A: Controlled Portion: Group 2 |
|---|---|---|
| Percentage of Subjects With Reduction in C3c Staining on Renal Biopsy at Week 12 | 50.0 (18.7 to 81.3) | 33.3 (0.8 to 90.6) |
C3c staining intensity is semi quantitatively graded on a scale of 0 to 3, in which negative, 1+, 2+ and 3+ staining corresponds to scores of 0 to 3, with 0 being absent and 3 being the highest intensity seen on immunofluorescence. Higher scores indicate worse outcome. Reduction in C3c staining was defined as decrease of at least 2 orders of magnitude of intensity from baseline. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.
| Percentage of participants | Part A: Non-controlled Portion: Group 1 | Part A: Non-controlled Portion: Group 2 |
|---|---|---|
| Percentage of Subjects With Reduction in C3c Staining on Renal Biopsy at Week 52 | 50.0 (18.7 to 81.3) | 66.7 (9.4 to 99.2) |
C3c staining intensity is semi quantitatively graded on a scale of 0 to 3, in which negative, 1+, 2+ and 3+ staining corresponds to scores of 0 to 3, with 0 being absent and 3 being the highest intensity seen on immunofluorescence. Higher scores indicate worse outcome. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects. Number of subjects who demonstrated a shift of C3c staining from baseline to Week 12 and baseline to Week 52 are presented.
| Participants | Part A: Non-controlled Portion: Group 1 | Part A: Non-controlled Portion: Group 2 |
|---|---|---|
| Shift from 3 at baseline to 0 at Week 12 | 3 | 0 |
| Shift from 2 at baseline to 0 at Week 12 | 1 | 0 |
| Shift from 3 at baseline to 1 at Week 12 | 1 | 1 |
| Shift from 2 at baseline to 3 at Week 12 | 0 | 1 |
| Shift from 3 at baseline to 0 at Week 52 | 4 | 1 |
| Shift from 2 at baseline to 0 at Week 52 | 0 | 1 |
| Shift from 3 at baseline to 1 at Week 52 | 1 | 0 |
| Shift from 2 at baseline to 3 at Week 52 | 1 | 0 |
eGFR was calculated by using Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) creatinine equation. Stabilization or improvement in eGFR was defined as no more than a 25% decrease relative to baseline. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.
| Percentage of participants | Part A: Non-controlled Portion: Group 1 | Part A: Non-controlled Portion: Group 2 |
|---|---|---|
| Percentage of Subjects With Stabilization or Improvement in Estimated Glomerular Filtration Rate (eGFR) at Week 52 | 70.0 | 66.7 |
Stabilization or improvement in serum creatinine was defined as no increase or an increase of no more than 25% from baseline. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.
| Percentage of participants | Part A: Non-controlled Portion: Group 1 | Part A: Non-controlled Portion: Group 2 |
|---|---|---|
| Percentage of Subjects With Stabilization or Improvement of Serum Creatinine Concentration at Week 52 | 70.0 | 66.7 |
Blood samples were collected at specified timepoints for analysis of eGFR which was calculated by using CKD-EPI creatinine equation. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.
| milliliter/minute/1.73 square meter | Part A: Non-controlled Portion: Group 1 | Part A: Non-controlled Portion: Group 2 |
|---|---|---|
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52 | 10.1 ± 32.67 | -10.3 ± 14.57 |
Blood samples were collected at specified timepoints for analysis of eGFR which was calculated by using CKD-EPI creatinine equation. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.
| percentage change | Part A: Non-controlled Portion: Group 1 | Part A: Non-controlled Portion: Group 2 |
|---|---|---|
| Percentage Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52 | 29.65 ± 78.707 | -16.67 ± 21.481 |
Blood samples were collected at specified timepoints for analysis of serum creatinine concentration. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.
| milligram per deciliter | Part A: Non-controlled Portion: Group 1 | Part A: Non-controlled Portion: Group 2 |
|---|---|---|
| Change From Baseline in Serum Creatinine Concentration at Week 52 | -0.044 ± 0.8368 | 0.267 ± 0.4619 |
Blood samples were collected at specified timepoints for analysis of serum creatinine concentration. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.
| percentage change | Part A: Non-controlled Portion: Group 1 | Part A: Non-controlled Portion: Group 2 |
|---|---|---|
| Percentage Change From Baseline in Serum Creatinine Concentration at Week 52 | 3.198 ± 59.5916 | 17.778 ± 30.7920 |
Collected over Treatment-emergent adverse events (TEAEs) and Treatment-emergent serious adverse events (TESAEs) were collected from first dose of study drug for Group 1 subjects or randomization for Group 2 subjects (Day 1) up to 56 days after the last dose of study drug, approximately 139 days for controlled and 333 days for non-controlled portion. All-cause mortality (deaths) were collected from first dose of study drug (Day 1) up to DCO of 19 January 2024, approximately 864 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Controlled Portion: Group 1 | 0/10 (0%) | 5/10 (50%) | 7/10 (70%) |
| Part A: Controlled Portion: Group 2 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Part A: Non-controlled Portion: Group 1 | 0/10 (0%) | 5/10 (50%) | 8/10 (80%) |
| Part A: Non-controlled Portion: Group 2 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Event | Part A: Controlled Portion: Group 1 | Part A: Controlled Portion: Group 2 | Part A: Non-controlled Portion: Group 1 | Part A: Non-controlled Portion: Group 2 |
|---|---|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 1/10 | 0/3 | 2/10 | 0/3 |
| Nephropathy toxicRenal and urinary disorders | 1/10 | 0/3 | 1/10 | 0/3 |
| Renal tubular disorderRenal and urinary disorders | 1/10 | 0/3 | 0/10 | 0/3 |
| Urinary tract obstructionRenal and urinary disorders | 0/10 | 0/3 | 1/10 | 0/3 |
| Arthritis bacterialInfections and infestations | 0/10 | 0/3 | 1/10 | 0/3 |
| Genital herpes simplexInfections and infestations | 1/10 | 0/3 | 1/10 | 0/3 |
| Pneumocystis jirovecii infectionInfections and infestations | 0/10 | 0/3 | 1/10 | 0/3 |
| PneumoniaInfections and infestations | 0/10 | 0/3 | 1/10 | 0/3 |
| NeutropeniaBlood and lymphatic system disorders | 1/10 | 0/3 | 0/10 | 0/3 |
| Cardiac failureCardiac disorders | 0/10 | 0/3 | 1/10 | 0/3 |
| Event | Part A: Controlled Portion: Group 1 | Part A: Controlled Portion: Group 2 | Part A: Non-controlled Portion: Group 1 | Part A: Non-controlled Portion: Group 2 |
|---|---|---|---|---|
| COVID-19Infections and infestations | 2/10 | 1/3 | 1/10 | 0/3 |
| InfluenzaInfections and infestations | 1/10 | 1/3 | 0/10 | 0/3 |
| Tinea versicolourInfections and infestations | 0/10 | 1/3 | 0/10 | 0/3 |
| NasopharyngitisInfections and infestations | 0/10 | 0/3 | 1/10 | 1/3 |
| Herpes zosterInfections and infestations | 0/10 | 0/3 | 0/10 | 1/3 |
| DiarrhoeaGastrointestinal disorders | 1/10 | 1/3 | 0/10 | 1/3 |
| NauseaGastrointestinal disorders | 1/10 | 0/3 | 0/10 | 1/3 |
| Rectal haemorrhageGastrointestinal disorders | 0/10 | 0/3 | 0/10 | 1/3 |
| AnaemiaBlood and lymphatic system disorders | 1/10 | 1/3 | 1/10 | 1/3 |
| Weight decreasedInvestigations | 1/10 | 1/3 | 0/10 | 0/3 |
The intent-to-treat (ITT) population included all subjects who were randomized.
| Age, Continuous(Years) | Part A: Controlled Portion: Group 1 | Part A: Controlled Portion: Group 2 | Total |
|---|---|---|---|
| Mean | 39.8 ± 12.59 | 44.3 ± 24.03 | 40.8 ± 14.80 |
| Sex: Female, Male(Participants) | Part A: Controlled Portion: Group 1 | Part A: Controlled Portion: Group 2 | Total |
|---|---|---|---|
| Female | 5 | 1 | 6 |
| Male | 5 | 2 | 7 |
| Race/Ethnicity, Customized(Participants) | Part A: Controlled Portion: Group 1 | Part A: Controlled Portion: Group 2 | Total |
|---|---|---|---|
| White | 9 | 3 | 12 |
| Not reported | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Part A: Controlled Portion: Group 1 | Part A: Controlled Portion: Group 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 9 | 2 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2021 to primary completion in Feb 2023, 17 months.
Results were first posted in Feb 2025, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegcetacoplan
Glomerulonephritis, Membranoproliferative →
Apellis Pharmaceuticals, Inc. →